SUPN

#1830
Supernus Pharmaceuticals, Inc. - Common Stock
43.9 4 USD
0.00%
Market Price
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
43.71
43.96
Year Range
42.45
59.68
Daily Change
+0.46%
Monthly Change
-12.90%
6 month change
-19.03%
Year Change
-18.63%
Previous Close
43.7 4
Open
43.8 5
Low
43.7 1
High
43.9 6
Volume
57
Open full chart

Financials

Overview Statement Statistics Documents

2026

Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SUPERNUS PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K

SUPERNUS PHARMACEUTICALS, INC. current report, 17 June 2022

Full document

Business Context and Reporting Period

This Form 8-K Current Report from Supernus Pharmaceuticals, Inc. covers the date of June 17, 2022. The filing reports on the results of the Company's Annual Meeting of Stockholders held on that date.

Key Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is a corporate governance report regarding shareholder voting outcomes.

Material Changes and Voting Results

As of April 18, 2022, there were 53,407,811 shares of common stock outstanding and entitled to vote. The stockholders approved the following proposals:

  • Proposal 1 (Election of Class I Directors):
    • Carrolee Barlow, M.D., Ph.D.: 45,991,006 votes For; 859,944 votes Withheld.
    • Jack A. Khattar: 44,865,418 votes For; 1,985,532 votes Withheld.
    • Both directors were elected to serve until the 2025 Annual Meeting.
  • Proposal 2 (Ratification of Independent Auditor): KPMG LLP was ratified as the independent public accounting firm for the fiscal year ending December 31, 2022.
    • Votes For: 49,041,972
    • Votes Against: 14,144
    • Abstain: 9,180
  • Proposal 3 (Executive Compensation): The compensation paid to named executive officers was approved on a non-binding basis.
    • Votes For: 45,856,924
    • Votes Against: 832,225
    • Abstain: 161,801

Guidance, Outlook, and Risks

The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document is limited to the tabulation of votes and the submission of matters to security holders.

Investor Verification Checklist

  • Verify the definitive proxy statement filed on May 2, 2022, for detailed background on the director nominees and executive compensation.
  • Confirm the total number of shares outstanding (53,407,811) as of the record date of April 18, 2022.
  • Note the significant number of broker non-votes (2,214,346) recorded for the director election and executive compensation proposals.
  • Review subsequent filings for the Company's actual financial performance, as this 8-K contains no financial metrics.

News